CA
NZ
UK
AU
IND
US
…
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Humacyte is a clinical-stage regenerative medicine company developing human acellular vessels (HAVs), off-the-shelf bioengineered vascular grafts intended for vascular repair and hemodialysis access. Long-term growth may be driven by regulatory approvals, clinical adoption across dialysis and vascular indications, and scaling manufacturing capacity, which could support commercial use if trials and approvals succeed.
Key risks include clinical and regulatory failure, uncertain reimbursement and commercial adoption, complex manufacturing scale-up challenges and the need for ongoing capital to reach and sustain commercialization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -40.83M | -148.70M | -110.78M | -11.96M | -26.48M |
| Net income | -40.83M | -148.70M | -110.78M | 64.22M | 37.54M |
| Selling general administrative | 31.17M | 25.80M | 23.39M | 22.88M | 21.13M |
| Selling and marketing expenses | - | - | 3.00M | - | - |
| Gross profit | -15.01M | -7.19M | -76.55M | - | -0.05M |
| Reconciled depreciation | 7.34M | 7.19M | 8.00M | 8.21M | 8.24M |
| Ebit | -29.58M | -139.42M | -104.18M | -84.58M | -81.21M |
| Ebitda | -22.24M | -132.23M | -96.46M | -160.34M | -136.98M |
| Depreciation and amortization | 7.34M | 7.19M | 7.72M | -75.77M | -55.77M |
| Non operating income net other | - | - | - | 78.81M | 59.08M |
| Operating income | -107.44M | -114.40M | -100.05M | -84.58M | -81.21M |
| Other operating expenses | 109.47M | 114.40M | 100.05M | 84.58M | 81.21M |
| Interest expense | 11.25M | 9.28M | 6.60M | 6.20M | 4.35M |
| Interest income | 2.59M | 4.10M | 5.74M | 2.63M | 0.02M |
| Net interest income | -8.66M | -5.17M | -0.77M | -3.57M | -4.33M |
| Income tax expense | - | - | 3.11M | -76.18M | -64.01M |
| Total revenue | 2.04M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 92.43M | 107.21M | 23.50M | 84.58M | 81.21M |
| Cost of revenue | 17.05M | 7.19M | 76.55M | - | 0.05M |
| Total other income expense net | 66.60M | -34.30M | -10.73M | 72.61M | 54.73M |
| Net income from continuing ops | -40.83M | -148.70M | -89.39M | -11.96M | -26.48M |
| Net income applicable to common shares | - | - | - | -11.96M | -26.48M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 116.37M | 137.87M | 128.22M | 204.30M | 286.53M |
| Other current assets | 3.27M | 2.92M | 2.69M | 2.33M | 3.66M |
| Total liab | 113.26M | 190.54M | 114.68M | 87.37M | 164.36M |
| Total stockholder equity | 3.11M | -52.67M | 13.55M | 116.93M | 122.17M |
| Other current liab | 10.54M | 12.55M | 11.95M | 9.41M | 2.20M |
| Common stock | 0.02M | 0.01M | 0.01M | 543.47M | 536.75M |
| Capital stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -726.85M | -686.01M | -537.31M | -426.54M | -414.57M |
| Other liab | - | - | - | 27.97M | 104.84M |
| Cash | 50.50M | 44.94M | 80.59M | 149.77M | 217.50M |
| Total current liabilities | 18.37M | 19.95M | 18.44M | 19.58M | 11.05M |
| Current deferred revenue | - | - | -2.61M | - | 4.73M |
| Net debt | 14.35M | -28.40M | -22.49M | -102.01M | -169.03M |
| Short term debt | 2.43M | 2.92M | 2.61M | 8.57M | 2.03M |
| Short long term debt | - | - | - | 8.57M | - |
| Short long term debt total | 64.85M | 16.54M | 58.11M | 47.76M | 48.47M |
| Other stockholder equity | 729.94M | 633.33M | 550.85M | 543.46M | 536.24M |
| Property plant equipment | - | - | - | 30.04M | 35.03M |
| Total current assets | 67.80M | 47.86M | 83.28M | 154.21M | 229.34M |
| Net tangible assets | - | - | - | 116.93M | 122.17M |
| Short term investments | - | - | 0.00M | 2.11M | 8.00M |
| Net receivables | 0.44M | 0.00M | 0.00M | 0.03M | 0.18M |
| Long term debt | 35.44M | - | 38.60M | 20.34M | 27.36M |
| Inventory | 13.59M | 0.00M | - | -0.03M | - |
| Accounts payable | 5.40M | 4.49M | 6.49M | 1.59M | 2.09M |
| Accumulated other comprehensive income | - | - | 0.00M | - | -822.77M |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -426.54M | -414.57M |
| Non currrent assets other | 0.67M | 51.46M | 0.03M | 20.05M | 0.73M |
| Non current assets total | 48.57M | 90.01M | 44.95M | 50.09M | 57.19M |
| Capital lease obligations | 29.40M | 16.54M | 18.91M | 21.79M | 21.11M |
| Long term debt total | - | - | - | 20.34M | 27.36M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -1.57M | 5.19M | 5.89M | -8.00M |
| Change to liabilities | - | - | - | -0.43M | 1.72M |
| Total cashflows from investing activities | -0.88M | -1.57M | -0.17M | 4.84M | -8.22M |
| Net borrowings | 37.03M | -2.58M | -34.07M | -1.98M | 29.66M |
| Total cash from financing activities | 61.49M | 114.18M | 4.51M | -1.45M | 266.98M |
| Change to operating activities | - | - | - | 1.39M | -0.30M |
| Net income | -40.83M | -148.70M | -110.78M | -11.96M | -26.48M |
| Change in cash | -44.44M | 14.49M | -69.18M | -67.73M | 177.57M |
| Begin period cash flow | 95.29M | 80.80M | 149.77M | 217.50M | 39.93M |
| End period cash flow | 50.85M | 95.29M | 80.59M | 149.77M | 217.50M |
| Total cash from operating activities | -105.04M | -98.12M | -73.31M | -71.13M | -81.19M |
| Issuance of capital stock | 103.45M | 89.05M | 0.00M | - | - |
| Depreciation | 5.33M | 7.19M | 7.72M | 8.21M | 8.24M |
| Dividends paid | 0.00M | 0.00M | - | - | - |
| Change to inventory | -21.83M | 0.00M | - | - | -0.18M |
| Change to account receivables | -0.26M | 0.00M | 0.03M | 0.14M | -0.06M |
| Sale purchase of stock | - | 0.71M | - | 0.54M | 243.00M |
| Other cashflows from financing activities | -88.34M | 70.84M | -1.76M | 4.84M | 268.71M |
| Change to netincome | - | - | - | -69.99M | -48.97M |
| Capital expenditures | 0.88M | 1.57M | 2.28M | 1.05M | 0.22M |
| Change receivables | - | - | - | 0.14M | -0.06M |
| Cash flows other operating | - | - | - | 3.42M | -14.56M |
| Cash and cash equivalents changes | - | - | - | -67.73M | 177.57M |
| Change in working capital | -23.39M | 0.31M | 6.57M | 1.03M | -0.56M |
| Stock based compensation | 9.75M | 6.14M | 6.83M | 6.18M | 10.15M |
| Other non cash items | -55.90M | 36.94M | 16.35M | -74.41M | -54.74M |
| Free cash flow | -105.93M | -99.69M | -75.58M | -72.18M | -81.41M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HUMA Humacyte Inc |
-0.04 9.09% |
0.41 | - | 35.84 | 72.25 | 5.04 | 67.78 | 4.34 |
| NVO Novo Nordisk A/S |
-1.88 4.45% |
40.30 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.17 0.21% |
547.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-13.89 1.49% |
916.78 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
2525 East North Carolina Highway 54, Durham, NC, United States, 27713
919 313 9633
184
| Name | Title | Year Born |
|---|---|---|
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, Pres, CEO & Director | 1963 |
| Mr. Dale A. Sander | CFO, Chief Corp. Devel. Officer & Treasurer | 1960 |
| Dr. Heather Ledbetter Prichard Ph.D. | Chief Operating Officer | 1978 |
| Dr. Juliana L. Blum Ph.D. | Co-Founder & Exec. VP of Corp. Devel. | NA |
| Ms. Sabrina Osborne | Exec. VP of Bus. Strategy & People | NA |
| Mr. William John Scheessele | Chief Commercial Officer | 1972 |
| Dr. Shamik J. Parikh M.D. | Chief Medical Officer | 1973 |
| Mr. Harold Alterson | Sr. VP of Quality | NA |
| Dr. Yang Cao M.D., Ph.D. | Chief Regulatory Officer | NA |
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, President, CEO & Director | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.69%
Communication Services
-1.01%
Consumer Cyclical
-1.38%
Consumer Defensive
-0.48%
Energy
-1.76%
Financial Services
-1.79%
Financials
-0.63%
Healthcare
-2.72%
Industrials
-2.48%
Real Estate
-1.04%
Technology
-5.27%
Utilities
-0.77%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+41.90%
Please wait processing your request...